Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Navidea Biopharmaceuticals Inc

(AMEX: NAVB)
Add to Portfolio
+0.08 (+7.69%)
as of Feb 20, 2020

Last 1.12
Change +0.08 (+7.69%)
Open 1.09
Prev. Close 1.04
Today's Range
1.05
1.14
52wk Range
0.49
4.20
Volume 266,239
Avg Volume 160,697
Sector SIC-2835 In Vitro & In Vivo Diagnostic Substances

Perfomance Comparison

Name Today 3-Month 1-Year
NAVB +7.69% +13.13% -62.67%
DJIA -0.44% +4.30% +12.58%
S&P 500 -0.38% +7.23% +21.13%

Key Statistics

Annual EPS -1.05
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 19,340
Weighted Alpha -32.03
Standard Deviation +1.20
Profit Margin N/A
Beta 0.82

Growth Rates

YTD -11.11%
1-Year -69.41%
3-Year -88.94%
5-Year -96.79%
10-Year -97.40%

Opinion

Sell Hold Buy

Recent Headlines

Navidea Biopharmaceuticals Regains Compliance with

BusinessWire via COMTEX - Fri Feb 14, 11:56AM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that following the recently-ann(full story)
NAVB: 1.12 (+0.08)

Navidea Biopharmaceuticals Announces $4.2 Million Sale

BusinessWire via COMTEX - Fri Feb 14, 07:28AM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed agreeme(full story)
NAVB: 1.12 (+0.08)

Navidea Biopharmaceuticals Obtains Partial Dismissal

BusinessWire via COMTEX - Mon Dec 30, 05:19PM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on December 26, 2019, the (full story)
NAVB: 1.12 (+0.08)

Navidea Biopharmaceuticals Announces $1.9 Million

BusinessWire via COMTEX - Fri Dec 06, 06:23PM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed agreeme(full story)
NAVB: 1.12 (+0.08)

Navidea Biopharmaceuticals to Present at the 12th

BusinessWire via COMTEX - Thu Dec 05, 03:45PM EST
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr. Jed Latkin, Chief Exec(full story)
NAVB: 1.12 (+0.08)